04/18/2024 7:48 PM | 4D Molecular Therapeutics (Issuer) Bizily Scott (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
04/10/2024 3:05 PM | 4D Molecular Therapeutics (Filer)
| Form DEF 14A | |
04/10/2024 3:06 PM | 4D Molecular Therapeutics (Filer)
| Form DEFA14A | |
04/10/2024 3:07 PM | 4D Molecular Therapeutics (Filer)
| Form ARS | |
04/03/2024 6:18 PM | 4D Molecular Therapeutics (Issuer) Bizily Scott (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/29/2024 3:52 PM | 4D Molecular Therapeutics (Issuer) Bizily Scott (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/20/2024 3:40 PM | 4D Molecular Therapeutics (Issuer) Bizily Scott (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
|
02/29/2024 5:01 PM | 4D Molecular Therapeutics (Issuer) Bizily Scott (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/29/2024 4:15 PM | 4D Molecular Therapeutics (Filer)
| Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
02/21/2024 4:41 PM | 4D Molecular Therapeutics (Issuer) Bizily Scott (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/14/2024 7:51 PM | 4D Molecular Therapeutics (Subject) Venrock Healthcare Capital Partners III, L.P. (Filed by)
| Form SC 13G/A | |
02/14/2024 8:56 AM | 4D Molecular Therapeutics (Subject) BIOTECHNOLOGY VALUE FUND L P (Filed by)
| Form SC 13G/A | |
02/14/2024 7:43 AM | 4D Molecular Therapeutics (Subject) Deep Track Capital, LP (Filed by)
| Form SC 13G/A | |
02/13/2024 9:56 AM | 4D Molecular Therapeutics (Subject) JANUS HENDERSON GROUP PLC (Filed by)
| Form SC 13G/A | |
02/12/2024 8:04 PM | 4D Molecular Therapeutics (Issuer) Bizily Scott (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/12/2024 7:22 PM | 4D Molecular Therapeutics (Issuer) Kirn David (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/08/2024 3:50 PM | 4D Molecular Therapeutics (Subject) Kirn David (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
02/07/2024 7:32 PM | 4D Molecular Therapeutics (Issuer) Kim Robert Young (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/07/2024 6:42 PM | 4D Molecular Therapeutics (Issuer) Kim Robert Young (Reporting)
| Form 3/A | |
02/05/2024 4:27 PM | 4D Molecular Therapeutics (Filer)
| Form 424B5 | |
02/05/2024 3:35 PM | 4D Molecular Therapeutics (Filer)
| Form S-3ASR | |
01/25/2024 3:59 PM | 4D Molecular Therapeutics (Subject) BlackRock Inc. (Filed by)
| Form SC 13G/A | |
01/23/2024 3:50 PM | 4D Molecular Therapeutics (Subject) Kirn David (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
01/08/2024 3:15 PM | 4D Molecular Therapeutics (Subject) VIKING GLOBAL INVESTORS LP (Filed by)
| Form SC 13G/A | |
01/08/2024 3:19 PM | 4D Molecular Therapeutics (Issuer) Kirn David (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/05/2024 4:44 PM | 4D Molecular Therapeutics (Issuer) HALVORSEN OLE ANDREAS (Reporting) Ott David C. (Reporting) Shabet Rose Sharon (Reporting) VIKING GLOBAL INVESTORS LP (Reporting) Viking Global Opportunities GP LLC (Reporting) Viking Global Opportunities Illiquid Investments Sub-Master LP (Reporting) Viking Global Opportunities Parent GP LLC (Reporting) Viking Global Opportunities Portfolio GP LLC (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/05/2024 3:49 PM | 4D Molecular Therapeutics (Subject) Kirn David (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
01/04/2024 4:48 PM | 4D Molecular Therapeutics (Subject) Kirn David (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
01/04/2024 7:30 AM | 4D Molecular Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
12/18/2023 4:16 PM | 4D Molecular Therapeutics (Subject) Kirn David (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
12/15/2023 4:24 PM | 4D Molecular Therapeutics (Subject) Kirn David (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
11/22/2023 3:20 PM | 4D Molecular Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
11/09/2023 3:20 PM | 4D Molecular Therapeutics (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
11/09/2023 3:23 PM | 4D Molecular Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
09/26/2023 8:33 PM | 4D Molecular Therapeutics (Issuer) Mehra Uneek (Reporting)
| Form 3 Initial statement of beneficial ownership of securities | |
09/12/2023 8:17 PM | 4D Molecular Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
08/15/2023 11:15 PM | 4D Molecular Therapeutics (Filer)
| Form EFFECT | |
07/10/2023 8:31 PM | 4D Molecular Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
06/12/2023 5:23 PM | 4D Molecular Therapeutics (Issuer) Bizily Scott (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/06/2023 6:23 PM | 4D Molecular Therapeutics (Issuer) Bizily Scott (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/25/2023 6:39 PM | 4D Molecular Therapeutics (Issuer) Tomasello Shawn (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
“Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad) See this before next week's Fed Meeting
Thousands of investing ideas come across his desk every year… But Doc Eifrig just revealed THIS ONE "will go down as one of the smartest and most lucrative financial moves of the decade." (Last time we shared this, it led to a 995% gain.) Get the free details now. |
05/25/2023 6:42 PM | 4D Molecular Therapeutics (Issuer) MILLIGAN JOHN F (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/25/2023 6:31 PM | 4D Molecular Therapeutics (Issuer) Kasahara Noriyuki (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/25/2023 6:32 PM | 4D Molecular Therapeutics (Issuer) Chacko Jacob (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/25/2023 6:33 PM | 4D Molecular Therapeutics (Issuer) GRAY SUSANNAH (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/25/2023 6:35 PM | 4D Molecular Therapeutics (Issuer) THEUER CHARLES (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/25/2023 6:37 PM | 4D Molecular Therapeutics (Issuer) Miller-Rich Nancy (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/16/2023 7:52 PM | 4D Molecular Therapeutics (Issuer) Moretti August J (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/11/2023 4:50 PM | 4D Molecular Therapeutics (Issuer) HALVORSEN OLE ANDREAS (Reporting) Ott David C. (Reporting) Shabet Rose Sharon (Reporting) VIKING GLOBAL INVESTORS LP (Reporting) Viking Global Opportunities GP LLC (Reporting) Viking Global Opportunities Illiquid Investments Sub-Master LP (Reporting) Viking Global Opportunities Parent GP LLC (Reporting) Viking Global Opportunities Portfolio GP LLC (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/04/2023 7:09 PM | 4D Molecular Therapeutics (Issuer) Kirn David (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/04/2023 3:31 PM | 4D Molecular Therapeutics (Filer)
| Form 424B5 | |
05/03/2023 8:51 PM | 4D Molecular Therapeutics (Filer)
| Form S-8 POS | |
04/25/2023 5:43 PM | 4D Molecular Therapeutics (Issuer) Chacko Jacob (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
04/25/2023 5:44 PM | 4D Molecular Therapeutics (Issuer) Bizily Scott (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |